Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Sponsored Research and Clinical Trial Agreements (Tables)

Sponsored Research and Clinical Trial Agreements (Tables)

9 Months Ended

Sep. 30, 2021

Schedule of Research and Development for Sponsored Research and Clinical Trial Agreements

For the three and nine months ended September 30, 2021 and 2020, Aevitas recorded the following expense in connection with its sponsored research and clinical trial agreements:


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
($ in thousands)	2021		2020		2021		2020
UMass SRA	$	17		163	$	289	$	218
UPenn SRA		—		—		—		567
Total	$	17	$	163	$	289	$	785

Mustang [Member]

Schedule of Research and Development for Sponsored Research and Clinical Trial Agreements

For the three and nine months ended September 30, 2021 and 2020, Mustang recorded the following expense in research and development for sponsored research and clinical trial agreements:


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
($ in thousands)	2021		2020		2021		2020
City of Hope National Medical Center	$	—	$	—	$	—	$	500
IL13Rα2 (MB-101)		199		96		992		422
CD123 (MB-102)		24		48		250		344
CS1 (MB-104)		138		65		510		835
HER2 (MB-103)		319		—		473		—
PSCA (MB-105)		23		—		69		—
Fred Hutchinson Cancer Research Center - CD20 (MB-106)		492		418		1,490		1,134
St. Jude Children's Research Hospital - XSCID (MB-107)		330		107		610		1,665
Mayo Clinic		231		—		464		—
Total	$	1,756	$	734	$	4,858	$	4,900

Oncogenuity [Member]

Schedule of Research and Development for Sponsored Research and Clinical Trial Agreements

Oncogenuity


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
($ in thousands)	2021		2020		2021		2020
Columbia	$	187	$	125	$	562	$	250
Oxford		91		—		265		—
McCormick Labs		56		—		178		—
Total	$	334	$	125	$	1,005	$	250